[Intravitreal pegaptanib sodium for myopic choroidal neovascularization: 1 year results of a prospective pilot study].
To evaluate ophthalmologic outcomes 1 year after intravitreal pegaptanib sodium injection in patients with myopic choroidal neovascularization (CNV). We investigated 31 eyes of 30 patients who had been given intravitreal pegaptanib sodium (0.3 mg) injections for subfoveal or juxtafoveal myopic CNV at 6-week intervals from July through December 2009. We compared visual acuity, retinal sensitivity within the central 12 degrees and maximum lesion diameter, and quantified metamorphopsia using M-CHARTS (Inami Co., Tokyo) both before and after the intravitreal injections. The Wilcoxon test was applied to identify statistically significant differences. Mean logMAR visual acuity was 0.49 +/- 0.38 before and 0.47 +/- 0.35 after treatment (p = 0.56); the corresponding values for mean retinal sensitivity were 7.48 +/- 3.69 dB and 8.15 +/- 4.18 dB (p = 0.24). Mean maximum lesion diameter was significantly reduced from 1,217 microm to 1,041 microm after treatment (p = 0.0021). Mean metamorphopsia scores were significantly improved after treatment, i.e., 0.85 +/- 0.68 to 0.50 +/- 0.39 for vertical lines (p = 0.016); 0.81 +/- 0.74 to 0.47 +/- 0.41 for horizontal lines (p = 0.017). The average number of injections was 3.1. No patient experienced adverse events associated with treatment. Visual acuity and retinal sensitivity were maintained, while metamorphopsia was improved 1 year after intravitreal pegaptanib sodium injections for myopic CNV.